Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims

1. (Currently Amended) A method for the treatment of a cancer comprising co-administering an anti-tumor antibody directed against the MN antigen and a cytokine to a subject in need thereof, wherein the cytokine is administered continuously or repeatedly in a low-dose form.

2. (Currently Amended) A method for the treatment of a cancer comprising co-administering an anti-tumor antibody directed against the MN antigen and cytokine to a subject in need thereof, wherein the method comprises:

(a) a first treatment stage comprising administering a low-dose cytokine, and

(b) a second treatment stage comprising co-administering ~~an~~ the anti-tumor antibody and a low-dose cytokine.

3. (Previously Presented) The method of claim 1, wherein the low-dose cytokine comprises a dose which is pharmaceutically effective in the substantial absence of NIC CTC toxicity grade 3 or higher.

4. (Previously Presented) The method according to claim 1 comprising a daily administration of a low-dose cytokine.

5. (Previously Presented) The method according to claim 1 wherein the cytokine is selected from interleukins and interferons.

6. (Original) The method of claim 5 wherein the cytokine is IL-2.

7. (Original) The method of claim 6 wherein the dose of IL-2 is in the range of from 1-10 MIU daily.

8. (Original) The method of claim 5 wherein the cytokine is IFN-α.

9. (Original) The method of claim 8 wherein the dose of IFN-α is in the range of from 1-10 MIU three times a week.

10. (Previously Presented) The method of claim 1 wherein the cytokine is administered in a substantially constant dose during the treatment.

11. (Previously Presented) The method of claim 1 wherein the cytokine is administered in a variable dose during the treatment.

12. (Previously Presented) The method of claim 1 wherein the cytokine is administered subcutaneously.

13. (Currently Amended) The method of claim 1 wherein the antitumor antibody is selected from antibodies directed against the MN (G250) ~~antigent~~ antigen.

14. (Previously Presented) The method of claim 1 wherein the antitumor antibody is a chimeric or humanized G250 antibody or a fragment thereof.

15. (Previously Presented) The method of claim 1 wherein the antitumor antibody is administered in intervals of from 5-20 days.

16. (Original) The method of claim 2 wherein the first treatment stage comprises 5-20 days.

17. (Original) The method of claim 2 wherein the second treatment stage comprises 50-200 days.